Robust Bayesian nonlinear mixed-effects modeling of time to positivity in tuberculosis trials
Author:
Affiliation:
1. Department of Statistics; University of Pretoria; Pretoria South Africa
2. Department of Mathematical Statistics and Actuarial Science; University of the Free State; Bloemfontein South Africa
3. IQVIA, Biostatistics; Bloemfontein South Africa
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology,Statistics and Probability
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/pst.1877/fullpdf
Reference29 articles.
1. Clinical development of anti-tuberculosis drugs;Mitchison;J Antimicrob Chemother,2006
2. Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB;Svensson;J Antimicrob Chemother,2017
3. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials;Phillips;BMC Med,2016
4. Biomarkers for tuberculosis disease activity, cure, and relapse;Wallis;Lancet Infect Dis,2009
5. Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials;Weiner;J Clin Microbiol,2010
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial;The Journal of Infectious Diseases;2024-03-25
2. A flexible multi‐metric Bayesian framework for decision‐making in Phase II multi‐arm multi‐stage studies;Statistics in Medicine;2023-12
3. Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial;The Lancet Infectious Diseases;2023-07
4. Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis;Antimicrobial Agents and Chemotherapy;2020-03-24
5. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial;The Lancet Respiratory Medicine;2019-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3